Torthaí cuardaigh - Evidio Domingo‐Musibay
- 1 - 7 toradh as 7 á dtaispeáint
-
1
Oncolytic measles virus strains as novel anticancer agents de réir Pavlos Msaouel, Mateusz Opyrchal, Evidio Domingo‐Musibay, Evanthia Galanis
Foilsithe / Cruthaithe 2013Revisão -
2
Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncologic Patients de réir Can Özütemiz, Luke A. Krystosek, An L. Church, Anil Chauhan, Jutta Ellermann, Evidio Domingo‐Musibay, Daniel Steinberger
Foilsithe / Cruthaithe 2021Artigo -
3
Oncolytic measles virus strains have significant antitumor activity against glioma stem cells de réir Cory Allen, Mateusz Opyrchal, Ileana Aderca, Mark A. Schroeder, Jann N. Sarkaria, Evidio Domingo‐Musibay, Mark J. Federspiel, Evanthia Galanis
Foilsithe / Cruthaithe 2012Artigo -
4
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma de réir Evidio Domingo‐Musibay, Paari Murugan, Alessio Giubellino, Sandeep Sharma, Daniel Steinberger, Jianling Yuan, Matthew A. Hunt, Emil Lou, Jeffrey S. Miller
Foilsithe / Cruthaithe 2018Artigo -
5
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma de réir Amod A. Sarnaik, Omid Hamid, Nikhil I. Khushalani, Karl D. Lewis, Theresa Medina, Harriet M. Kluger, Sajeve Thomas, Evidio Domingo‐Musibay, Anna C. Pavlick, Eric D. Whitman, Salvador Martín‐Algarra, Pippa Corrie, Brendan D. Curti, Judit Oláh, Jose Lutzky, Jeffrey S. Weber, James Larkin, Wen Shi, Toshimi Takamura, Madan Jagasia, Harry Qin, Xiao Wu, Cécile Chartier, Friedrich Graf Finckenstein, Maria Fardis, John M. Kirkwood, Jason Chesney
Foilsithe / Cruthaithe 2021Artigo -
6
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint... de réir Jason Chesney, Karl D. Lewis, Harriet M. Kluger, Omid Hamid, Eric D. Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo‐Musibay, Giao Q. Phan, John M. Kirkwood, Jessica C. Hassel, Marlana Orloff, James Larkin, Jeffrey S. Weber, Andrew J.S. Furness, Nikhil I. Khushalani, Theresa Medina, Michael E. Egger, Friedrich Graf Finckenstein, Madan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod A. Sarnaik
Foilsithe / Cruthaithe 2022Artigo -
7
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial de réir Tina J. Hieken, Garth D. Nelson, Thomas J. Flotte, Eric P. Grewal, Jun Chen, Robert R. McWilliams, Lisa A. Kottschade, Lu Yang, Evidio Domingo‐Musibay, Roxana Dronca, Yiyi Yan, Svetomir N. Markovic, Anastasios Dimou, Heather N. Montane, Courtney L. Erskine, Mara A. Piltin, Daniel L. Price, Samir S. Khariwala, Jane Yuet Ching Hui, Carrie Strand, Susan M. Harrington, Vera J. Suman, Haidong Dong, Matthew S. Block
Foilsithe / Cruthaithe 2024Artigo
Uirlisí cuardaigh:
Ábhair a bhaineann le hábhar
Medicine
Cancer research
Internal medicine
Biology
Cancer
Melanoma
Oncology
Immunotherapy
Surgery
Vaccination
Breast cancer
Disease
Gastroenterology
Gene
Genetics
Measles
Measles virus
Metastatic melanoma
Oncolytic virus
Pembrolizumab
Progressive disease
Regimen
Virology
Virus
Adjuvant
Adult stem cell
Allele
Atezolizumab
Axillary Lymphadenopathy
Biochemistry